This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2022 May;89(3):313-314.

doi: 10.1016/j.rhum.2021.10.560. Epub 2021 Oct 21.

Impact de la COVID-19 sur l’initiation des prescriptions des biothérapies dans les maladies inflammatoires chroniques

[Article in French]

Pascal Richette^{1

2}, Matthieu Allez³, Vincent Descamps⁴, Lucas Perray⁵, Simon Pilet⁵, Augustin Latourte^{1

2}, Milka Maravic⁵

Affiliations

Affiliations

¹ Rheumatology department, Lariboisière Hospital, AP-HP, Paris, France.
² Inserm U1132, Paris University, Paris, France.
³ Gastro Enterology department, St-Louis Hospital, AP-HP, Paris, France.
⁴ Dermatology department, Bichat Hospital, AP-HP, Paris, France.
⁵ IQVIA, La Défense, France.

PMID: 34697532
PMCID: PMC8529531
DOI: 10.1016/j.rhum.2021.10.560

Impact de la COVID-19 sur l’initiation des prescriptions des biothérapies dans les maladies inflammatoires chroniques

[Article in French]

Pascal Richette et al. Rev Rhum Ed Fr. 2022 May.

. 2022 May;89(3):313-314.

doi: 10.1016/j.rhum.2021.10.560. Epub 2021 Oct 21.

Authors

Pascal Richette^{1

2}, Matthieu Allez³, Vincent Descamps⁴, Lucas Perray⁵, Simon Pilet⁵, Augustin Latourte^{1

2}, Milka Maravic⁵

Affiliations

¹ Rheumatology department, Lariboisière Hospital, AP-HP, Paris, France.
² Inserm U1132, Paris University, Paris, France.
³ Gastro Enterology department, St-Louis Hospital, AP-HP, Paris, France.
⁴ Dermatology department, Bichat Hospital, AP-HP, Paris, France.
⁵ IQVIA, La Défense, France.

PMID: 34697532
PMCID: PMC8529531
DOI: 10.1016/j.rhum.2021.10.560

No abstract available

PubMed Disclaimer

Figures

Fig. 1 — Fig. 1
Évolution de la proportion de patients ayant eu au moins 1 délivrance d’une biothérapie ou d’un inhibiteur de Janus kinase initié en 2020 et comparée à celle de 2019. Confinement : du 16 mars au 10 mai 2020 ; ABA : abatacept, JAKi : Janus kinase inhibiteur ; Initiation : Traitement non dispensé dans les 12 mois précédents.

See this image and copyright information in PMC

References

1. Landewé R.B.M., Machado P.M., Kroon F., et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020;79:851–858. - PubMed
1. Vilcu A.M., Blanchon T., Sabatte L., et al. Cross-validation of an algorithm detecting acute gastroenteritis episodes from prescribed treatment dispensing data in France: comparison with clinical data reported in a primary care surveillance system, winter seasons 2014/15 to 2016/17. BMC Med Res Methodol. 2019;19:110. - PMC - PubMed

LinkOut - more resources

Full Text Sources